AVTX
Income statement / Annual
Last year (2023), Avalo Therapeutics, Inc.'s total revenue was $1.92 M,
a decrease of 89.34% from the previous year.
In 2023, Avalo Therapeutics, Inc.'s net income was -$31.54 M.
See Avalo Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.92 M
|
$18.05 M
|
$5.40 M
|
$6.70 M
|
$6.75 M
|
$18.33 M
|
$27.81 M
|
$1.15 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.28 M |
$3.43 M |
$1.49 M |
$300,000.00 |
$11.63 M |
$7.48 M |
$635,648.00 |
$8.24 M |
$23,508.00 |
$9.50 M |
| Gross Profit |
$640,000.00 |
$14.62 M |
$3.91 M |
$6.40 M |
-$4.88 M |
$10.85 M |
$27.18 M |
-$7.09 M |
-$23,508.00 |
-$9.50 M |
| Gross Profit Ratio |
0.33 |
0.81 |
0.72 |
0.96 |
-0.72 |
0.59 |
0.98 |
-6.15 |
0 |
0 |
| Research and Development
Expenses |
$13.78 M
|
$31.31 M
|
$59.84 M
|
$32.19 M
|
$11.76 M
|
$5.79 M
|
$4.37 M
|
$10.15 M
|
$6.59 M
|
$12.24 M
|
| General & Administrative
Expenses |
$10.27 M
|
$20.64 M
|
$21.83 M
|
$17.42 M
|
$10.12 M
|
$10.68 M
|
$7.94 M
|
$7.08 M
|
$4.42 M
|
$4.88 M
|
| Selling & Marketing
Expenses |
$33,000.00
|
$76,000.00
|
$2.83 M
|
$2.34 M
|
$1.48 M
|
$8.52 M
|
$973,345.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.30 M
|
$20.71 M
|
$24.66 M
|
$19.76 M
|
$11.61 M
|
$19.20 M
|
$8.91 M
|
$7.08 M
|
$4.42 M
|
$4.88 M
|
| Other Expenses |
$0.00 |
$38,000.00 |
$1.55 M |
$1.74 M |
$1.34 M |
$13,657.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$640,000.00 |
$52.06 M |
$86.04 M |
$53.69 M |
$24.71 M |
$29.52 M |
$13.29 M |
$17.23 M |
$11.01 M |
$17.12 M |
| Cost And Expenses |
$25.37 M |
$55.49 M |
$87.53 M |
$53.99 M |
$24.14 M |
$37.00 M |
$13.92 M |
$17.23 M |
$11.01 M |
$17.12 M |
| Interest Income |
$0.00 |
$4.17 M |
$2.39 M |
$49,000.00 |
$121,326.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$3.42 M |
$4.17 M |
$2.39 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$793,205.00 |
$1.21 M |
| Depreciation &
Amortization |
$158,000.00
|
$166,000.00
|
$1.66 M
|
$1.84 M
|
$1.46 M
|
$1.85 M
|
$425,476.00
|
$26,856.00
|
$23,508.00
|
$28,943.00
|
| EBITDA |
-$27.96 M
|
-$37.29 M
|
-$80.50 M
|
-$45.45 M
|
-$17.36 M
|
-$13.07 M
|
$14.35 M
|
-$16.05 M
|
-$10.46 M
|
-$17.09 M
|
| EBITDA Ratio |
-14.53 |
-2.07 |
-14.93 |
-3.76 |
-2.57 |
0.35 |
0.52 |
-14.01 |
0 |
0 |
| Operating Income Ratio
|
-12.19
|
-2.07
|
-15.22
|
-4.02
|
-2.58
|
-2.15
|
0.5
|
-13.95
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$8.09 M
|
-$4.19 M
|
-$2.41 M
|
$5.67 M
|
$12.26 M
|
$54,928.00
|
-$53,640.00
|
-$391,556.00
|
$519,844.00
|
$1.06 M
|
| Income Before Tax |
-$31.53 M |
-$41.63 M |
-$84.55 M |
-$67.18 M |
-$15.99 M |
-$40.09 M |
$13.84 M |
-$16.47 M |
-$10.49 M |
-$16.06 M |
| Income Before Tax Ratio
|
-16.39
|
-2.31
|
-15.66
|
-10.03
|
-2.37
|
-2.19
|
0.5
|
-14.29
|
0
|
0
|
| Income Tax Expense |
$14,000.00 |
$28,000.00 |
-$196,000.00 |
-$2.79 M |
$280,000.00 |
-$33,910.00 |
$1.97 M |
$364,144.00 |
-$543,508.00 |
-$1.06 M |
| Net Income |
-$31.54 M |
-$41.66 M |
-$84.35 M |
-$64.38 M |
-$16.27 M |
-$40.05 M |
$11.87 M |
-$16.47 M |
-$10.49 M |
-$16.06 M |
| Net Income Ratio |
-16.4 |
-2.31 |
-15.63 |
-9.61 |
-2.41 |
-2.19 |
0.43 |
-14.29 |
0 |
0 |
| EPS |
-113.58 |
-1062.65 |
-2330.66 |
-2523.77 |
-819.74 |
-3317.28 |
1209.6 |
-5371.95 |
-13571.83 |
0 |
| EPS Diluted |
-113.58 |
-1062.65 |
-2330.66 |
-2523.77 |
-819.74 |
-3317.28 |
1209.6 |
-5371.95 |
-13571.83 |
0 |
| Weighted Average Shares
Out |
$277,727.00
|
$39,202.00
|
$36,191.00
|
$25,511.00
|
$19,849.00
|
$12,074.00
|
$6,392.36
|
$3,066.11
|
$772.92
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$277,727.00
|
$39,202.00
|
$36,191.00
|
$25,511.00
|
$19,849.00
|
$12,074.00
|
$6,512.08
|
$3,066.11
|
$772.92
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
